The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Uptake Mechanism of ApoE-Modified Nanoparticles on Brain Capillary Endothelial Cells as a Blood-Brain Barrier Model
Open accessAbstract
BACKGROUND: The blood-brain barrier (BBB) represents an insurmountable obstacle for most drugs thus obstructing an effective treatment of many brain diseases. One solution for overcoming this barrier is a transport by binding of these drugs to surface-modified nanoparticles. Especially apolipoprotein E (ApoE) appears to play a major role in the nanoparticle-mediated drug transport across the BBB. However, at present the underlying mechanism is incompletely understood. METHODOLOGY/PRINCIPAL FINDINGS: In this study, the uptake of the ApoE-modified nanoparticles into the brain capillary endothelial cells was investigated to differentiate between active and passive uptake mechanism by flow cytometry and confocal laser scanning microscopy. Furthermore, different in vitro co-incubation experiments were performed with competing ligands of the respective receptor. CONCLUSIONS/SIGNIFICANCE: This study confirms an active endocytotic uptake mechanism and shows the involvement of low density lipoprotein receptor family members, notably the low density lipoprotein receptor related protein, on the uptake of the ApoE-modified nanoparticles into the brain capillary endothelial cells. This knowledge of the uptake mechanism of ApoE-modified nanoparticles enables future developments to rationally create very specific and effective carriers to overcome the blood-brain barrier.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
Nanoparticulate systems for brain delivery of drugs.
Kreuter, J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00122-8 · Cited by 1,107 · cited 1×
“It could be shown, for example, by means of two-dimensional polyacrylamid gel electrophoresis that after injection into the blood stream, apolipoprotein E (ApoE) was adsorbed onto the surface of polysorbate 80-coated nanoparticles, which then could enter the BBB [25,26].”
BackgroundTHE CELL BIOLOGY OF THE BLOOD-BRAIN BARRIER
Rubin, L. L., & Staddon, J. M. (1999) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.22.1.11 · Cited by 1,000
Nanoparticulate systems for brain delivery of drugs
Kreuter, J. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.015 · Cited by 958
Self-citationLRP: a multifunctional scavenger and signaling receptor
Herz, J., & Strickland, D. K. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13992 · Cited by 908
Apolipoprotein E: Structure-Function Relationships
Weisgraber, K. H. (1994) · Advances in Protein Chemistry · doi:10.1016/s0065-3233(08)60642-7 · Cited by 830
Microencapsulation : methods and industrial applications
Benita, S. (1996) · Medical Entomology and Zoology · Cited by 806
Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier.
Kreuter, J., Shamenkov, D., Petrov, V., Ramge, P., Cychutek, K., Koch-Brandt, C., & Alyautdin, R. (2002) · Journal of drug targeting · doi:10.1080/10611860290031877 · Cited by 801 · cited 6×
“Therefore, it was hypothesized that these nanoparticles resemble endogenously circulating lipoproteins [27,29,30] and are taken up by a receptormediated pathway by the brain endothelial cells which express the respective receptors [6,22,24,27,29,30,31].”
BackgroundInfluentialSelf-citationElectrical resistance across the blood-brain barrier in anaesthetized rats: a developmental study.
Butt, A. M., Jones, H. C., & Abbott, N. J. (1990) · The Journal of Physiology · doi:10.1113/jphysiol.1990.sp018243 · Cited by 775
Optimization of the preparation process for human serum albumin (HSA) nanoparticles
Langer, K., Balthasar, S., Vogel, V., Dinauer, N., von Briesen, H., & Schubert, D. (2003) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(03)00134-0 · Cited by 757
Self-citation
Cited by
Effect of the surface modification, size, and shape on cellular uptake of nanoparticles
Salatin, S., Maleki Dizaj, S., & Yari Khosroushahi, A. (2015) · Cell Biology International · doi:10.1002/cbin.10459 · Cited by 625
Drug delivery to the central nervous system by polymeric nanoparticles: What do we know?
Kreuter, J. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.008 · Cited by 554
Self-citationTranscytosis to Cross the Blood Brain Barrier, New Advancements and Challenges
Pulgar, V. M. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.01019 · Cited by 482
Albumin nanostructures as advanced drug delivery systems
Karimi, M., Bahrami, S., Ravari, S. B., Zangabad, P. S., Mirshekari, H., Bozorgomid, M., Shahreza, S., Sori, M., & Hamblin, M. R. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1193149 · Cited by 422
Targeting Receptor-Mediated Transport for Delivery of Biologics Across the Blood-Brain Barrier
Lajoie, J. M., & Shusta, E. V. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124852 · Cited by 399
Corona Composition Can Affect the Mechanisms Cells Use to Internalize Nanoparticles
Francia, V., Yang, K., Deville, S., Reker-Smit, C., Nelissen, I., & Salvati, A. (2019) · ACS Nano · doi:10.1021/acsnano.9b03824 · Cited by 300
Nanoparticle–protein corona complexes govern the biological fates and functions of nanoparticles
Gunawan, C., Lim, M., Marquis, C. P., & Amal, R. (2014) · Journal of Materials Chemistry B · doi:10.1039/c3tb21526a · Cited by 277
The protein corona and its effects on nanoparticle-based drug delivery systems
Li, H., Wang, Y., Tang, Q., Yin, D., Tang, C., He, E., Zou, L., & Peng, Q. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.05.019 · Cited by 265
Bicker, J., Alves, G., Fortuna, A., & Falcão, A. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.03.012 · Cited by 262
Lipid nanoparticle-mediated drug delivery to the brain
Khare, P., Edgecomb, S. X., Hamadani, C. M., Tanner, E. E. L., & S Manickam, D. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114861 · Cited by 187
The potential of protein–nanomaterial interaction for advanced drug delivery
Peng, Q., & Mu, H. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.041 · Cited by 134
Neves, A. R., Queiroz, J. F., Weksler, B., Romero, I. A., Couraud, P.-O., & Reis, S. (2015) · Nanotechnology · doi:10.1088/0957-4484/26/49/495103 · Cited by 122
Nagpal, K., Singh, S. K., & Mishra, D. N. (2013) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2013.04.024 · Cited by 116
Leyva-Gómez, G., Cortés, H., Magaña, J. J., Leyva-García, N., Quintanar-Guerrero, D., & Florán, B. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.02.009 · Cited by 102
Enhancing autophagy in Alzheimer's disease through drug repositioning
Eshraghi, M., Ahmadi, M., Afshar, S., Lorzadeh, S., Adlimoghaddam, A., Rezvani Jalal, N., West, R., Dastghaib, S., Igder, S., Torshizi, S. R. N., et al. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108171 · Cited by 89
Evolving new-age strategies to transport therapeutics across the blood-brain-barrier
Choudhari, M., Hejmady, S., Narayan Saha, R., Damle, S., Singhvi, G., Alexander, A., Kesharwani, P., & Kumar Dubey, S. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120351 · Cited by 74
Refining in vitro models for nanomaterial exposure to cells and tissues
Guggenheim, E. J., Milani, S., Röttgermann, P. J. F., Dusinska, M., Saout, C., Salvati, A., Rädler, J. O., & Lynch, I. (2018) · NanoImpact · doi:10.1016/j.impact.2018.02.008 · Cited by 36
Mazura, A. D., & Pietrzik, C. U. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041268 · Cited by 9
Self-citation
Metadata
- Authors
- Wagner, S., Zensi, A., Wien, S. L., Tschickardt, S. E., Maier, W., Vogel, T., Worek, F., Pietrzik, C. U., Kreuter, J., & von Briesen, H.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-03-01
- Volume
- 7
- Issue
- 3
- Pages
- e32568
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2018361874
- Cited by
- 257
- References
- 55
- FWCI
- 8.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.